Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment-Reference-Cited by-同舟云学术

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment

Published:2018-04 Issue:4 Volume:34 Page:337-342
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

DeJesus Edwin¹,Haas Bernard²,Segal-Maurer Sorana³,Ramgopal Moti N.⁴,Mills Anthony⁵,Margot Nicolas⁶,Liu Ya-Pei⁶,Makadzange Tariro⁶,McCallister Scott⁶

Affiliation:

1. Orlando Immunology Center, Orlando, Florida.

2. Department für Gastroenterologie mit Infektiologie, LKH Graz South-West, Graz, Austria.

3. Department of Infectious Diseases, NewYork-Presbyterian Queens, Flushing, New York.

4. Midway Immunology Center, Ft. Pierce, Florida.

5. Southern California Men's Medical Group, Los Angeles, California.

6. Gilead Sciences, Inc., Foster City, California.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2017.0203

Reference16 articles.

1. Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects

2. Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy

3. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients

4. Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release;European Journal of Medicinal Chemistry;2024-10

2. Comparative Metabolic Effects of Integrase Inhibitor and Emtricitabine-Containing Tenofovir Derivatives in People Living with HIV: A Multi-Center Retrospective Analysis;2024-08-09

3. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11

4. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts;HIV Medicine;2023-12-26

5. Preventive and Sexual Health in LGBTQ+ Older Adults;Clinics in Geriatric Medicine;2023-11